Stem cell-based therapy in cardiac repair after myocardial infarction : Promise, challenges, and future directions
Copyright © 2023. Published by Elsevier Ltd..
Stem cells represent an attractive resource for cardiac regeneration. However, the survival and function of transplanted stem cells is poor and remains a major challenge for the development of effective therapies. As two main cell types currently under investigation in heart repair, mesenchymal stromal cells (MSCs) indirectly support endogenous regenerative capacities after transplantation, while induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) functionally integrate into the damaged myocardium and directly contribute to the restoration of its pump function. These two cell types are exposed to a common microenvironment with many stressors in ischemic heart tissue. This review summarizes the research progress on the mechanisms and challenges of MSCs and iPSC-CMs in post-MI heart repair, introduces several randomized clinical trials with 3D-mapping-guided cell therapy, and outlines recent findings related to the factors that affect the survival and function of stem cells. We also discuss the future directions for optimization such as biomaterial utilization, cell combinations, and intravenous injection of engineered nucleus-free MSCs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:188 |
|---|---|
| Enthalten in: |
Journal of molecular and cellular cardiology - 188(2024) vom: 18. März, Seite 1-14 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yan, Wenjun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Induced pluripotent stem cell-derived cardiomyocytes |
|---|
| Anmerkungen: |
Date Completed 04.03.2024 Date Revised 03.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.yjmcc.2023.12.009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367365790 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367365790 | ||
| 003 | DE-627 | ||
| 005 | 20240403235253.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240122s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.yjmcc.2023.12.009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1363.xml |
| 035 | |a (DE-627)NLM367365790 | ||
| 035 | |a (NLM)38246086 | ||
| 035 | |a (PII)S0022-2828(23)00213-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yan, Wenjun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Stem cell-based therapy in cardiac repair after myocardial infarction |b Promise, challenges, and future directions |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.03.2024 | ||
| 500 | |a Date Revised 03.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier Ltd. | ||
| 520 | |a Stem cells represent an attractive resource for cardiac regeneration. However, the survival and function of transplanted stem cells is poor and remains a major challenge for the development of effective therapies. As two main cell types currently under investigation in heart repair, mesenchymal stromal cells (MSCs) indirectly support endogenous regenerative capacities after transplantation, while induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) functionally integrate into the damaged myocardium and directly contribute to the restoration of its pump function. These two cell types are exposed to a common microenvironment with many stressors in ischemic heart tissue. This review summarizes the research progress on the mechanisms and challenges of MSCs and iPSC-CMs in post-MI heart repair, introduces several randomized clinical trials with 3D-mapping-guided cell therapy, and outlines recent findings related to the factors that affect the survival and function of stem cells. We also discuss the future directions for optimization such as biomaterial utilization, cell combinations, and intravenous injection of engineered nucleus-free MSCs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Induced pluripotent stem cell-derived cardiomyocytes | |
| 650 | 4 | |a Ischemic heart disease | |
| 650 | 4 | |a Mesenchymal stromal cell | |
| 650 | 4 | |a Metabolism | |
| 700 | 1 | |a Xia, Yunlong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Huishou |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Xiaoming |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Xinliang |e verfasserin |4 aut | |
| 700 | 1 | |a Tao, Ling |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of molecular and cellular cardiology |d 1970 |g 188(2024) vom: 18. März, Seite 1-14 |w (DE-627)NLM00001964X |x 1095-8584 |7 nnns |
| 773 | 1 | 8 | |g volume:188 |g year:2024 |g day:18 |g month:03 |g pages:1-14 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.yjmcc.2023.12.009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 188 |j 2024 |b 18 |c 03 |h 1-14 | ||